Pharmacogenetics of Acenocoumarol

Thromboembolic Diseases Clinical Trial

Official title: Stabilization of Anticoagulation by Acenocoumarol: Role of Genetic Vulnerability and Risk of Drug Interactions

Status Completed

Clinical Trial Summary

The use of oral anticoagulation is marked by an elevated risk of adverse drug events (ADE) due to a narrow therapeutic window leading to important medical and economical consequences. The risk of ADE is increased partly by drug interactions and recently identified genetic factors influencing the metabolism of coumarins (polymorphism of the cytochrome P450 CYP2C9) as well as the target enzyme of the coumarins (polymorphism of the vitamin K epoxide reductase complex subunit 1 (VKORC1).

The objective is to determine the impact of several genotypes on acenocoumarol treatment and on vulnerability to drug-drug interactions.

Clinical Trial Description

n/a

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Thromboembolic Diseases
• Thromboembolism

• NCT number: NCT01492777
• Study type: Observational
• Source: University Hospital, Geneva
• Status: Completed
• Phase: N/A
• Start date: November 2008
• Completion date: March 2012